Rhumbline Advisers Humacyte, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Humacyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 109,450 shares of HUMA stock, worth $499,091. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109,450
Previous 110,919
1.32%
Holding current value
$499,091
Previous $532,000
11.84%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HUMA
# of Institutions
153Shares Held
35.4MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$32.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$23.1 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$21.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$5.78 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $470M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...